Provided by Tiger Trade Technology Pte. Ltd.

HANSOH PHARMA

32.960
-0.960-2.83%
Volume:5.68M
Turnover:190.48M
Market Cap:199.87B
PE:30.27
High:34.560
Open:34.040
Low:32.920
Close:33.920
52wk High:43.587
52wk Low:27.658
Shares:6.06B
HK Float Shares:6.06B
Volume Ratio:1.36
T/O Rate:0.09%
Dividend:0.49
Dividend Rate:1.47%
EPS(LYR):1.089
ROE:19.40%
ROA:9.08%
PB:4.52
PE(LYR):30.27
PS:10.74

Loading ...

Hansoh Pharma's Application for Osteosarcoma Drug Accepted in China

MT Newswires Live
·
Sep 24

Hansoh Pharma’s BLA for B7-H3 ADC HS-20093 Accepted by China’s NMPA

Bulletin Express
·
Sep 24

Hansoh Pharma's HS-20093 Osteosarcoma Marketing Application Accepted by China's NMPA

Stock News
·
Sep 24

Hansoh Pharmaceutical - Biologics License Application of Risvutatug Rezetecan for Injection (Hs-20093) for Osteosarcoma Accepted by Nmpa

THOMSON REUTERS
·
Sep 24

BOCOM Intl Raises Hansoh Pharma Target Price to HK$46, Reiterates Buy Rating

Stock News
·
Sep 24

Movement Alert|HANSOH PHARMA Falls 3.09% in Regular Trading, Pharmaceuticals Sector Broadly Under Pressure

Market Focus
·
Sep 24

Hansoh Pharma Releases 2026 Interim Report and Promotes E-Communication Options for Registered Shareholders

Bulletin Express
·
Sep 23

Hansoh Pharma Publishes 2026 Interim Report; Shareholders Urged to Use Digital Access, Free Print Copies on Request

Bulletin Express
·
Sep 23

HANSOH PHARMA H1 2026 Profit Jumps 35.8% on Double-Digit Revenue Growth and Innovation Push

Bulletin Express
·
Sep 23

Hansoh Pharmaceutical Group Stock Falls 1.1% in Hong Kong

Dow Jones
·
Sep 23

Hansoh Pharma's Osteosarcoma Drug Included in Chinese Regulator's Priority Review

MT Newswires Live
·
Sep 22

Hansoh Pharmaceutical Says Risvutatug Rezetecan Included in NMPA Priority Review

Reuters
·
Sep 22

Hansoh Pharma's Osteosarcoma Therapy Gains NMPA Priority Review Designation

Stock News
·
Sep 22

Hansoh Pharmaceutical - Risvutatug Rezetecan for Injection Included in Nmpa Priority Review for Osteosarcoma

THOMSON REUTERS
·
Sep 22

Hansoh Pharma's Novel Autoimmune Drug Meets Phase 3 Goals, Sets Sights on Regulatory Submission

Deep News
·
Sep 21

Hansoh Pharmaceutical Group Stock Rises 3.7% in Hong Kong

Dow Jones
·
Sep 21

Hansoh Rises on Positive Clinical Trial Results for Plaque Psoriasis Drug

Reuters
·
Sep 21

Movement Alert|HANSOH PHARMA Rises 3.03% in Regular Trading, TYK2 Inhibitor HS-10374 Hits Phase III Primary Endpoints in Psoriasis Trial

Market Focus
·
Sep 21

Hansoh Pharma Says Phase 3 HS-10374 Psoriasis Trial Meets Co-Primary Endpoints

Reuters
·
Sep 21

Hansoh Pharmaceutical - Hs-10374 Meets Co-Primary Endpoints in Phase Iii Plaque Psoriasis Trial

THOMSON REUTERS
·
Sep 21